



Varian Medical Systems, Inc.  
% Mr. Peter J. Coronado  
Senior Director, Regulatory Affairs  
3100 Hansen Way  
PALO ALTO CA 94304

July 8, 2019

Re: K191580

Trade/Device Name: BRAVOS Afterloader Family: BRAVOS Afterloader System, Transfer Guide  
Tubes and Length Assessment Device

Regulation Number: 21 CFR 892.5700

Regulation Name: Remote controlled radionuclide applicator system

Regulatory Class: Class II

Product Code: JAQ

Dated: June 12, 2019

Received: June 14, 2019

Dear Mr. Coronado:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR

803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

For

Thalia T. Mills, Ph.D.  
Director  
Division of Radiological Health  
OHT7: Office of In Vitro Diagnostics  
and Radiological Health  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)

K191580

Device Name

BRAVOS Afterloader Family: BRAVOS Afterloader System, Transfer Guide Tubes, and Length Assessment Device

Indications for Use (Describe)

The BRAVOS Afterloader System is intended for use in the treatment of both benign and malignant disease or other conditions, for both curative and palliative intent, in the delivery of remote-controlled High Dose Rate (HDR) brachytherapy.

The Transfer Guide Tubes are intended to connect between the BRAVOS Remote Afterloader system and its range of Applicators. This connection creates a conduit for the source cable to travel through and allows the radioactive isotopes to be positioned within the patient's tumor site.

The Length Assessment Device is intended to allow the user to establish an approximate length of an unknown length channel prior to the afterloader performing definitive length verification.

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

### CONTINUE ON A SEPARATE PAGE IF NEEDED.


This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
PRASStaff@fda.hhs.gov

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*



**Varian Medical Systems**

3100 Hansen Way  
Palo Alto, CA 94304

650.493.4000  
800.544.4636

varian.com

## Premarket Notification 510(K) Summary

K191580

The following information is provided according to 21 CFR 807.92.

|                   |   |
|-------------------|---|
| <b>Submitter:</b> | <p>Varian Medical Systems, Inc.<br/>3100 Hansen Way Palo Alto, CA 94304</p> <p>Contact Name: Peter J. Coronado<br/>Phone: 650.424.6320<br/>Fax: 650.646.9200<br/>E-mail: submissions.support@varian.com</p> <p>Date Prepared: June 12, 2019</p> |
|-------------------|---|

|  |  |  |
|--|--|--|
| <b>Trade/<br/>Proprietary<br/>Names:</b> | <p><a href="#">BRAVOS Afterloader Family (K191580)</a></p> <ul style="list-style-type: none"> <li>• BRAVOS Afterloader System</li> <li>• Transfer Guide Tubes (TGT)</li> <li>• Length Assessment Device (LAD)</li> </ul>   |  |
|  | <p><b>BRAVOS Afterloader System, Transfer Guide Tubes (TGT), Length Assessment Device (LAD)</b></p>  |  |
|  | <p><b>Classification Name:</b><br/>Remote controlled radionuclide applicator system, 21 CFR §892.5700</p> <p><b>Common/Usual Name:</b><br/><b>Afterloader System</b><br/>Source Guide Tubes<br/>Brachytherapy Accessory</p> <p><b>Regulatory Class:</b><br/>Class II</p> <p><b>Product Code:</b><br/>JAQ</p> | <p><b>Predicate Device:</b><br/><a href="#">BRAVOS Afterloader Family (K181903)</a></p> <ul style="list-style-type: none"> <li>• <b>BRAVOS Afterloader System</b></li> <li>• <b>Transfer Guide Tubes (TGT)</b></li> <li>• <b>Length Assessment Device (LAD)</b></li> </ul> |

|                             |  |  |
|-----------------------------|--|--|
| <b>Device Description:</b>  | <b><u>BRAVOS Afterloader System</u></b>  |  |
|                             | The <b>BRAVOS Afterloader System</b> is a computer controlled remote electro/mechanical system used for automatically placing a cable incorporating an irradiated iridium pellet (sealed source) internally or close by a malignant tumor or tumor bed in a practice known as Brachytherapy.                   |  |
|                             | <b><u>Transfer Guide Tubes (TGT)</u></b>   |  |
|                             | The <b>Transfer Guide Tubes (TGT)</b> are Brachytherapy applicator accessories. They are designed to provide a path for the dummy and source cable from the BRAVOS Afterloader System to the Applicator. The applicator end of a Transfer Guide Tube can vary in design to accommodate a range of Applicators. |  |
|                             | <b><u>Length Assessment Device (LAD)</u></b>   |  |
|                             | The <b>Length Assessment Device (LAD)</b> is a Brachytherapy applicator accessory and is used to determine the approximate length of the inner lumen of the Transfer Guide Tubes (TGT) and applicator assembly.  |  |
| <b>Intended/Indications</b> | <i>The subject device's indications for use and the intended use <u>have not changed</u> since the predicate submission.</i>   |  |
| <b>For Use Statement:</b>   | <b><u>BRAVOS Afterloader System</u></b>  |  |
|                             | <b>Intended Use</b>  | <b>Indications for Use</b>   |
|                             | The BRAVOS Afterloader System is intended for use in the treatment of both benign and malignant disease or other conditions, for both curative and palliative intent, in the delivery of remote-controlled High Dose Rate (HDR) brachytherapy.   | The Bravos Afterloader System is indicated for use in the treatment of both benign and malignant disease or other conditions, for both curative and palliative intent, in the delivery of remote-controlled High Dose Rate (HDR) brachytherapy.  |
|                             | <b><u>Transfer Guide Tubes (TGT)</u></b>   |  |
|                             | <b>Intended Use</b>  | <b>Indications for Use</b>   |
|                             | The Transfer Guide Tubes are intended to connect between the BRAVOS Remote Afterloader system and its range of Applicators. This connection creates a conduit for the source cable to travel through and allows the radioactive isotopes to be positioned within the patient's tumor site.                     | The Transfer Guide Tubes are intended to connect between the Bravos Remote Afterloader system and its range of applicators. This connection creates a conduit for the source cable to travel through and allows the radioactive isotopes to be positioned within the patient's tumor site. |
|                             | <b><u>Length Assessment Device (LAD)</u></b>   |  |
|                             | <b>Intended Use</b>  | <b>Indications for Use</b>   |
|                             | The Length Assessment Device is intended to allow the user to establish an approximate length of an unknown length channel prior to the afterloader performing definitive length verification.   | The Length Assessment Device is intended to allow the user to establish an approximate length of an unknown length channel prior to the afterloader performing definitive length verification.   |

The purpose of this Special 510(k) submission is to provide details on the updated **BRAVOS Afterloader System** which is a part of the **Varian's BRAVOS Afterloader Family (K181903)** for which we are claiming substantial equivalence. There have been no updates to the accessories **Transfer Guide Tubes (TGT)** and **Length Assessment Device (LAD)** since the previous submission (**K181903**). The indications for use and the intended use are identical in the subject device as for the predicate.

**Note:** Varian's updated **BRAVOS Afterloader System** was developed under the project name "**G3**" and "**MR1**" and the control software under the project name "**Jaguar**" which will be referenced in the design documentation as such.

## Comparison of Technological Characteristics with the Predicate Device

At a high level, the subject and predicate devices are based on the following similar technological elements:

### **BRAVOS Afterloader System:**

- Same Intended Use and Indications for Use
- Similar Design and Technology
- Similar **Jaguar** Console Software (*subject device updated to version 2.1*)

### Transfer Guide Tubes (TGT) and Length Assessment Device (LAD):

- Same as Predicate device (*no changes in the subject device*)

## Significant Difference

**BRAVOS Afterloader System:** The significant differences compared to the predicate device are

- BRAVOS Control Software (**Jaguar** version 2.1) to accommodate Multi-Part Plans
- Modified Emergency Drive Behavior

The **BRAVOS Afterloader System** is remote-controlled afterloading device for brachytherapy. The system utilizes a small, high activity Iridium-192 source that is encapsulated in a steel capsule, which is fixed to a stainless-steel cable and moves into applicator(s) or catheter(s) inserted into the patient.

In addition to the changes listed above, other cumulative non-significant changes since the predicate device include the following:

- Firmware:
  - Minor enhancements and bug fixes for the connection to Service PC and loading Source Cable (Product Service Engineer-use only)
- Jaguar:
  - Minor enhancements and bug fixes to improve loading large plans and dwell time values
  - Show patient picture on treatment reports
- Service:
  - Minor enhancements and bug fixes to reduce parameters that are reset during source exchange and clarify names on sensor labels (Product Service Engineer-use only)

## Performance Data

Software verification and validation was conducted and documentation was provided as recommended by FDA's Guidance for Industry and FDA Staff, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices." The software for **BRAVOS Afterloader System** was considered as a "major" level of concern.

Varian's **BRAVOS Afterloader Family** which consists of the **updated BRAVOS Afterloader System** is substantially equivalent to the predicate device (*K181903*). Compared to the predicate device, the basic operation and technological characteristics are substantially the same. The above changes do not affect the intended use or indications for use of the **BRAVOS Afterloader System**.

No animal studies or clinical tests have been included in this pre-market submission.

Verification testing was performed to demonstrate that the performance and functionality of the **updated BRAVOS Afterloader System** meets the initial design input requirements. Verification testing was performed to verify the integrity of any changes. Validation testing was performed on production equivalent devices, under clinically representative conditions by qualified personnel.

## **Standards Conformance**

The subject device conforms in whole or in part with the following standards:

- AAMI/ ANSI 60601-1: 2005
- IEC 60601-1-2: 2014
- IEC 60601-1-8:2006 + A1:2012
- IEC 60601-2-17:2013
- IEC 62304: 2006
- IEC 60601-1-6: 2013-10
- IEC 60825-1: 2007
- EN ISO 10993-1:2009
- EN ISO 10993-5:2009
- EN ISO 10993-10: 2010
- EN ISO 10993-18:2009
- AAMI TIR-12:2010
- AAMI TIR-30: 2011
- EN ISO 17664:2004
- IEC 62366:2007/(R)2014
- EN ISO 14971:2012

The subject device also complies with the following non-FDA recognized standard:

- EN ISO 13485:2016

## **Conclusion**

The non-clinical data for the **updated BRAVOS Afterloader System** from the **BRAVOS Afterloader Family** supports the safety of the device and the software verification and validation demonstrates that the subject device should perform as intended in the specified use conditions. Varian therefore considers the **updated BRAVOS Afterloader System** from the **BRAVOS Afterloader Family** to be safe and effective and are substantially equivalent to the predicate.